State-of-the-art non-targeted metabolomics in the study of chronic kidney disease
Here we report a metabolomics discovery study conducted on blood serum samples of patients in different stages of chronic kidney disease (CKD). Metabolites were monitored on a quality controlled holistic platform combining reversed-phase liquid chromatography coupled to high-resolution quadrupole time-of-flight mass spectrometry in both negative and positive ionization mode and gas chromatography coupled to quadrupole mass spectrometry. A substantial portion of the serum metabolome was thereby covered. Eighty-five metabolites were shown to evolve with CKD progression of which 43 metabolites were a confirmation of earlier reported uremic retention solutes and/or uremic toxins. Thirty-one unique metabolites were revealed which were increasing significantly throughout CKD progression, by a factor surpassing the level observed for creatinine, the currently used biomarker for kidney function. Additionally, 11 unique metabolites showed a decreasing trend.
KeywordsChronic kidney disease Metabolomics GC–MS LC–MS Q-TOF Serum
The authors acknowledge Steve Fischer (Agilent Technologies, Santa Clara, CA), Gordon Ross (Agilent Technologies, Cheadle, UK) and Kai Chen (Ghent University, Belgium) for their valuable input. This research was funded by the Flemish Agency for Innovation by Science and Technology (IWT, Flanders). JB was supported by an IWT study grant.
- Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300.Google Scholar
- Chen, J., Zhao, X., Fritsche, J., et al. (2008). Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Analytical Chemistry, 80(4), 1280–1289.CrossRefPubMedGoogle Scholar
- Cohen, G., Raupachova, J., Wimmer, T., Deicher, R., & Hörl, W. H. (2008). The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients. Nephrol. Dialysis Transplantation, 23(8), 2512–2519.CrossRefGoogle Scholar
- Dasgupta, A., Kenny, M. A., & Ahmad, S. (1990). Abnormal fatty-acid profile in chronic-haemodialysis patients—Possible deficiency of essential fatty-acids. Clinical Physiology & Biochemistry, 8, 238–243.Google Scholar
- Dudley, E., Tuytten, R., Bond, A., et al. (2005). Study of the mass spectrometric fragmentation of pseudouridine: comparison of fragmentation data obtained by matrix-assisted laser desorption/ionisation post-source decay, electrospray ion trap multistage mass spectrometry, and by a method utilising electrospray quadrupole time-of-flight tandem mass spectrometry and in-source fragmentation. Rapid Communications in Mass Spectrometry, 19, 3075–3085.CrossRefPubMedGoogle Scholar
- Hayashi, K., Sasamura, H., Hishiki, T., et al. (2011). Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1–2 chronic kidney disease. Nephro-Urology Monthly, 3(3), 164–171.Google Scholar
- Lawrence, J. R., Peter, R., Baxter, G. J., Robson, J., Graham, A. B., & Paterson, J. R. (2003). Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. Journal of Clinical Pathology, 56(9), 651–653.CrossRefPubMedPubMedCentralGoogle Scholar
- Lipkin, G. W., Forbes, M. A., Cooper, E. H., & Turney, J. H. (1993). Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 8(4), 357–360.Google Scholar
- Mischak, H., Allmaier, G., Apweiler, R., et al. (2010). Recommendations for biomarker identification and qualification in clinical proteomics. Science Translational Medicicne, 2(46), 46ps42.Google Scholar
- Palazoglu, M., & Fiehn, O. (2009). Metabolite identification in blood plasma using GC/MS and the Agilent Fiehn GC/MS metabolomics RTL library. Agilent Application Note 5990-3638EN. Palo Alto, CA: Agilent Technologies.Google Scholar